Brief: PharmaTher Submits Application for KETARX to FDA
06/09/2023 12:55
Sept 6 (Reuters) - Pharmather Holdings Ltd PHRM.CD :
* PHARMATHER SUBMITS PRIORITY ORIGINAL ABBREVIATED NEW DRUG
APPLICATION FOR KETARX™ (KETAMINE) TO THE FDA
Source text for Eikon: ID:nGNX4hS7pY
Further company coverage: PHRM.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmather Holdings
See all newsBrief: Pharmather Sells Ketamine ANDA, Eyes Over $25M In Milestone And Profit-Sharing Payments
Brief: Pharmather receives US FDA approval goal date for Ketamine
Brief: Pharmather Announces Update On FDA New Drug Application For Ketamine
Brief: PharmTther Announces Post Complete Response Letter Clarification Meeting Request Granted From The FDA For Ketamine Abbreviated New Drug Application
Brief: Pharmather Receives Complete Response Letter From The U.S. Food And Drug Administration For Ketamine Abbreviated New Drug Application